CARE Ratings (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
CARE Ratings Limited |
|||
|
Price: ₹1,346.20 | ||
| 52 Week Low: ₹891.00 52 Week High: ₹1,571.00 |
|||
| Market Capital: 4,079.09 Crore (Smallcap) | |||
| Financial Services -> Financial Data & Stock Exchanges | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: CARE Ratings Share Price Target For 2024
- 1.1.1: CARE Ratings Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: CARE Ratings Share Price Target For 2025
- 1.2.1: CARE Ratings Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: CARE Ratings Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: CARE Ratings Brief Company Overview
- 4: CARE Ratings Financial Performance
- 4.0.1: Is CARE Ratings A Good Buy For Long Term?
To predict the CARE Ratings's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
CARE Ratings Share Price Target For 2024
The line chart displays the monthly closing prices of CARE Ratings with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for CARE Ratings shares in 2024, see the table below.
CARE Ratings Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 1413.0 (+4.96%) | Price Action: 06 Dec 2024 Low |
| 2024 Target 2 | 1396.15 (+3.71%) | Price Action: 14 Nov 2024 Low |
| 2024 Target 1 | 1382.24 (+2.67%) | Price Action: Mar 2017 High |
| Current Price | 1346.20 | CARE Ratings's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1332.25 (-1.04%) | Price Action: 19 Nov 2024 Low |
| Stop Loss 2 | 1316.15 (-2.24%) | Price Action: Nov 2024 Low |
| Stop Loss 3 | 1294.42 (-3.85%) | Price Action: Feb 2015 High |
Short-Term Technical Outlook
Current Technical Position: CARE Ratings is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹1396.13 serves as the nearest technical reference point.
Historical Returns: 3-month: +33.76% | 6-month: +28.56% | 1-year: +43.60%
CARE Ratings Share Price Target For 2025
The line chart displays the monthly closing prices of CARE Ratings with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for CARE Ratings shares in 2025, see the table below.
CARE Ratings Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1852.45 (+37.60%) | Price Action: Chart |
| 2025 Target 2 | 1817.91 (+35.04%) | Price Action: Chart |
| 2025 Target 1 | 1799.91 (+33.70%) | Fibonacci Extension Level 64.90% |
| Current Price | 1346.20 | CARE Ratings's share price as of 20 Dec 2024 |
| Stop Loss 1 | 1245.17 (-7.51%) | Price Action: Feb 2024 High |
| Stop Loss 2 | 1225.67 (-8.96%) | Price Action: Apr 2017 Low |
| Stop Loss 3 | 1211.03 (-10.05%) | Price Action: Apr 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: CARE Ratings is currently trading at 66.9% of its 52-week range (₹891 - ₹1571).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +43.60% | 3-year: +132.73% | 5-year: +139.81%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
CARE Ratings Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹1,346.20 | ||
| 2024 | ₹1,476.60 | +9.69% | ₹1,498.75 |
| 2025 | ₹2,020.16 | +36.81% | ₹2,050.46 |
| 2026 | ₹2,425.84 | +20.08% | ₹2,548.13 |
| 2027 | ₹3,305.03 | +36.24% | ₹3,354.61 |
| 2028 | ₹3,820.40 | +15.59% | ₹3,877.71 |
| 2029 | ₹4,480.01 | +17.27% | ₹4,547.21 |
| 2030 | ₹4,940.99 | +10.29% | ₹5,015.10 |
| 2031 | ₹5,146.50 | +4.16% | ₹5,575.72 |
| 2032 | ₹6,332.61 | +23.05% | ₹6,427.60 |
| 2033 | ₹6,778.19 | +7.04% | ₹6,879.86 |
| 2034 | ₹7,483.42 | +10.40% | ₹7,595.67 |
| 2035 | ₹7,861.82 | +5.06% | ₹7,979.75 |
| 2036 | ₹7,867.15 | +0.07% | ₹8,603.30 |
| 2037 | ₹9,360.19 | +18.98% | ₹9,500.59 |
| 2038 | ₹9,735.98 | +4.01% | ₹9,882.02 |
| 2039 | ₹9,931.87 | +2.01% | ₹10,080.85 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
CARE Ratings Brief Company Overview
CARE Ratings Limited: A Leading Credit Rating Agency Established in 1993, CARE Ratings Limited is a reputed credit rating agency in India, Mauritius, and Nepal. Recognized for its comprehensive rating and grading services, CARE plays a crucial role in the financial...
markets. Key Services: Rating services for financial instruments, structured finance, and insurance Infrastructure sector ratings, security receipts, and real estate Corporate governance ratings, project finance, and MLD valuation Advisory services, research, and analytics Diverse Product Range: CARE offers a wide range of services catering to the needs of corporates, financial institutions, banks, and institutional investors. Commitment: CARE is committed to providing unbiased, transparent, and accurate credit ratings to facilitate informed decision-making in the financial markets.CARE Ratings Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 4,079.09 Crore | Market valuation of CARE Ratings's shares. |
| Revenue (TTM) | 365.11 Crore | Total revenue generated by CARE Ratings over the past twelve months. |
| Net Income (TTM) | +1,143,650,944.00 | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +45.04% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +31.32% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+21.70% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+31.00% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
2.72 | Company's total debt divided by total shareholder equity. |
| Total Debt | 20.75 Crore | Sum of CARE Ratings's current & long-term financial obligations. |
| Total Cash | 86.95 Crore | Total amount of liquid funds available to CARE Ratings. |
| Beta | 1.07 | Beta is greater than 1 indicating that the CARE Ratings's price is more volatile than the market. |
Is CARE Ratings A Good Buy For Long Term?
CARE Ratings, a small-cap stock with a market capitalization of ₹4,079.09 crore, shows strong financial health. Its impressive 31.32% profit margin on ₹365.11 crore revenue (TTM) and positive growth trends (31% YoY earnings, 21.7% QoQ revenue growth) are encouraging. The company boasts a healthy cash balance of ₹86.95 crore against a debt of only ₹20.75 crore (Q2 2024-25). While past returns (39.92% in 3 months, 52.20% in 12 months, and 166.41% in 3 years) are excellent, long-term investors should note the inherent volatility of small-caps. Considering the financials, it's an average buy for the long term, warranting further in-depth analysis.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
